ERBB2 kinase domain mutation in the lung squamous cell carcinoma

Cancer Letters

Volumn 237, Issue 1, 2006, Pages 89-94

  Lee, Jong Woo ^a   Soung, Young Hwa ^a   Kim, Su Young ^a   Nam, Suk Woo ^a   Park, Won Sang ^a   Wang, Young Pil ^a   Jo, Keon Hyun ^a   Moon, Seok Whan ^a   Song, Sang Yong ^b   Lee, Jung Young ^a   Yoo, Nam Jin ^a   Lee, Sug Hyung ^a  

^a The Catholic University of Korea   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

ERBB2; Lung; Mutation; Squamous cell carcinoma

Indexed keywords

ADENOSINE TRIPHOSPHATE; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHATIDYLINOSITOL 3 KINASE;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ALPHA HELIX; AMINO ACID SUBSTITUTION; ARTICLE; CODON; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MUTATIONAL ANALYSIS; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; ONCOGENE; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN RNA BINDING; SIGNAL TRANSDUCTION; SINGLE STRAND CONFORMATION POLYMORPHISM; SOMATIC MUTATION; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; LARGE CELL CARCINOMA; LUNG TUMOR; MIDDLE AGED; MUTATION; PROTEIN TERTIARY STRUCTURE; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ERBB-2;

EID: 33745689525     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.05.026     Document Type: Article

References (22)

1. Gschwind A., Fischer O.M., and Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer 4 (2004) 361-370
2. Jorissen R.N., Walker F., Pouliot N., Garrett T.P., Ward C.W., and Burgess A.W. Epidermal growth factor receptor: mechanisms of activation and signaling. Exp. Cell Res. 284 (2003) 31-53
3. Manning G., Whyte D.B., Martinez R., Hunter T., and Sudarsanam S. The protein kinase complement of the human genome. Science 298 (2002) 1912-1934
4. Cohen C. Protein kinases-the major drug targets of the twenty-first century?. Nat. Rev. Drug Discov. 4 (2002) 309-315
5. Fabbro D., Ruetz S., Buchdunger E., Cowan-Jacob S.W., Fendrich G., Liebetanz J., et al. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol. Ther. 93 (2002) 79-98
6. Levitzki A. Protein kinase inhibitors as a therapeutic modality. Acc. Chem. Res. 36 (2003) 462-469
7. Carpenter G., and Cohen S. Epidermal growth factor. Epidermal growth factor. J. Biol. Chem. 265 (1990) 7709-7712
8. Yarden Y., and M X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2 (2001) 127-137
9. Cohen S., Ushiro H., Stoscheck C., and Chinkers M. A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J. Biol. Chem. 257 (1982) 1523-1531
10. Yarden Y., and Schlessinger J. Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry 26 (1987) 1443-1451
11. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
12. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
13. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptors gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA. 101 (2004) 13306-13311
14. Tokumo M., Toyooka S., Kiura K., Shigematsu H., Tomii K., Aoe M., et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin. Cancer Res. 11 (2005) 1167-1173
15. Lee J., Soung Y., Kim S., Park W., Nam S., Lee J., et al. Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer. Int. J. Cancer 113 (2005) 510-511
16. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17 (1999) 2639-2648
17. Hunter S.C., Bignell G., Edkins S., Davies H., et al. cancer: intragenic ERBB2 kinase mutations in tumours, Nature 431 (2004), Stephens pp. 525-526
18. Shigematsu H., Takahashi T., Nomura M., Majmudar K., Suzuki M., Lee H., et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 65 (2005) 1642-1646
19. Lee J.Y., Dong S.M., Kim S.Y., Yoo N.J., Lee S.H., and Park W.S. A simple, precise and economical microdissection technique for analysis of genomic DNA from archival tissue sections. Virchows Arch. 433 (1998) 305-309
20. Soung Y.H., Lee J.W., Kim S.Y., Jang J., Park Y.G., Park W.S., et al. CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas. Cancer Res. 65 (2005) 815-821
21. Lee J.W., Soung Y.H., Kim S.Y., Lee H.W., Park W.S., Nam S.W., et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24 (2005) 1477-1480
22. Rosell R. Toward customized trastuzumab in HER-2/neu-overexpressing non-small-cell lung cancers. J. Clin. Oncol. 22 (2004) 1171-1173